{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:45:41Z","timestamp":1789069541303,"version":"build-2803163510"},"reference-count":231,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,8,23]],"date-time":"2006-08-23T00:00:00Z","timestamp":1156291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00246-006-1289-0","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T11:05:43Z","timestamp":1156503943000},"page":"533-551","source":"Crossref","is-referenced-by-count":21,"title":["Future Pharmacologic Agents for Treatment of Heart Failure in Children"],"prefix":"10.1007","volume":"27","author":[{"given":"Brady S.","family":"Moffett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,8,23]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","volume":"86","author":"SD Anker","year":"2002","unstructured":"Anker SD, Coats AJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123\u2013130","journal-title":"Int J Cardiol"},{"key":"1289_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s002280000204","volume":"56","author":"S Antila","year":"2002","unstructured":"Antila S, Asko J, Honkanen T, Letonen L (2000) Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. Eur J Clin Pharmacol 56:705\u2013710","journal-title":"Eur J Clin Pharmacol"},{"key":"1289_CR3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00195930","volume":"49","author":"S Antila","year":"1996","unstructured":"Antila S, Eha J, Heinpalu M, et al. (1996) Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 49:451\u2013458","journal-title":"Eur J Clin Pharmacol"},{"key":"1289_CR4","first-page":"446","volume":"36","author":"S Antila","year":"1998","unstructured":"Antila S, Honkanen T, Lehtonen L, Neuvonen PJ (1998) The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium sensitizing drug levosimendan. Int J Clin Pharmacol Ther 36:446\u2013449","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1289_CR5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0928-0987(99)00048-2","volume":"9","author":"S Antila","year":"1999","unstructured":"Antila S, Huuskohen H, Nevalainen T, et al. (1999) Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 9:85\u201391","journal-title":"Eur J Pharm Sci"},{"key":"1289_CR6","first-page":"816","volume":"47","author":"S Antila","year":"1997","unstructured":"Antila S, Jarvinen A, Akkila J, et al. (1997) Studies on psychomotoric effects and pharmacokinetic drug interactions of the new calcium sensitizing drug levosimendan and ethanol. Arnzneimittelforschung 47:816\u2013820","journal-title":"Arnzneimittelforschung"},{"key":"1289_CR7","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0735-1097(02)02570-6","volume":"40","author":"E Azeka","year":"2002","unstructured":"Azeka E, Ramires JAF, Valler C, Bocchi EA (2002) Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J Am Coll Cardiol 40:2034\u20132038","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.CIR.103.7.981","volume":"103","author":"R Berger","year":"2001","unstructured":"Berger R, Stanek B, Hulsmann M, et al. (2001) Effects of endothelin A receptor blockade on endothelin function in patients with chronic heart failure. Circulation 103:981\u2013986","journal-title":"Circulation"},{"key":"1289_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00024382-199404000-00001","volume":"1","author":"P Boekstegers","year":"1994","unstructured":"Boekstegers P, Wedenhofer S, Zell R, et al. (1994) Repeated administration of a F(ab\u2019)2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1:237\u2013245","journal-title":"Shock"},{"key":"1289_CR10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.amjcard.2004.10.031","volume":"95","author":"WM Book","year":"2005","unstructured":"Book WM, Hott BJ, McConnell M (2005) B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 95:545\u2013546","journal-title":"Am J Cardiol"},{"key":"1289_CR11","unstructured":"Bosentan package insert (2003) Actelion Pharmaceuticals US South San Francisco,CA"},{"key":"1289_CR12","doi-asserted-by":"crossref","first-page":"l044","DOI":"10.1161\/01.CIR.103.8.1044","volume":"103","author":"B Bozkurt","year":"2001","unstructured":"Bozkurt B, Torre-Amione G, Warren M, et al. (2001) Results of targeted anti-tumor necrosis factor therapy with Etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:l044\u20131047","journal-title":"Circulation"},{"key":"1289_CR13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1053\/j.jvca.2004.08.020","volume":"18","author":"JP Braun","year":"2004","unstructured":"Braun JP, Schneider M, Dohmen P, Dopfmer U (2004) Succesful treatment of dilative cardiomyopathy in a 12-year-old girl using the calcium sensitizer levosimendan after weaning from mechanical biventricular assist support. J Cardiothorac Vasc Anesth 18:772\u2013774","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1289_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejcts.2004.03.034","volume":"26","author":"JP Braur","year":"2004","unstructured":"Braur JP, Schneider M, Kastrup M, Liu J (2004) Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg 26:228\u2013230","journal-title":"Eur J Cardiothorac Surg"},{"key":"1289_CR15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0008-6363(00)00253-4","volume":"49","author":"BR Brehm","year":"2001","unstructured":"Brehm BR, Wolf SC, Bertsch D, et al. (2001) Effects of nebivolol on proliferation and apsoptosis on human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 49:430\u2013439","journal-title":"Cardiovasc Res"},{"key":"1289_CR16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1388-9842(02)00113-7","volume":"4","author":"BR Brehm","year":"2002","unstructured":"Brehm BR, Wolf SC, Corner S, et al. (2002) Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 4:757\u2013763","journal-title":"Eur J Heart Fail"},{"key":"1289_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJM200002033420507","volume":"342","author":"ME Brickner","year":"2000","unstructured":"Brickner ME, Hillis LD, Lange RA (2000) Congenital heart disease in adults. N Engl J Med 342:252\u2013263","journal-title":"N Engl J Med"},{"key":"1289_CR18","doi-asserted-by":"crossref","first-page":"26L","DOI":"10.1016\/S0002-9149(97)00846-1","volume":"80","author":"MR Bristow","year":"1997","unstructured":"Bristow MR (1997) Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 80:26L\u201340L","journal-title":"Am J Cardiol"},{"key":"1289_CR19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/978-1-4615-4871-3_59","volume":"449","author":"R Brouard","year":"1998","unstructured":"Brouard R, Laporte V, Serradeil-Le Gal C, et al. (1998) Safety, tolerability, and pharmacokinetics of SR 49059, a VI a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv Exp Med Biol 449:455\u2013465","journal-title":"Adv Exp Med Biol"},{"key":"1289_CR20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1067\/mpd.2001.113045","volume":"138","author":"LA Bruns","year":"2001","unstructured":"Bruns LA, Chrisant MK, Lamour JM, et al. (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505\u2013511","journal-title":"J Pediatr"},{"key":"1289_CR21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9149(01)01581-8","volume":"88","author":"AJ Burger","year":"2001","unstructured":"Burger AJ, Elkayam U, Neibaur M, et al. (2001) Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine vs. nesiritide therapy. Am J Cardiol 88:35\u201339","journal-title":"Am J Cardiol"},{"key":"1289_CR22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2000","unstructured":"Burnier M (2000) Angiotensin II type I receptor blockers. Circulation 103:904\u2013912","journal-title":"Circulation"},{"key":"1289_CR23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s002280050685","volume":"55","author":"M Burnier","year":"1999","unstructured":"Burnier M, Fricker AF, Hayoz D, et al. (1999) Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1\/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 55:633\u2013637","journal-title":"Eur J Clin Pharmacol"},{"key":"1289_CR24","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1136\/adc.79.2.192","volume":"79","author":"H Campbell","year":"1998","unstructured":"Campbell H, Surry SAM, Royle EM (1998) A review of randomized controlled trial published in the Archives of Disease in Childhood from 1982\u201396. Arch Dis Child 79:192\u2013197","journal-title":"Arch Dis Child"},{"key":"1289_CR25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","volume":"5","author":"P Carson","year":"1999","unstructured":"Carson P, Ziesche S, Johnson G, et al. (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:178\u2013187","journal-title":"J Card Fail"},{"key":"1289_CR26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"Cascorbil","year":"2001","unstructured":"Cascorbil, Gerloff T, Johne A, et al. (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174","journal-title":"Clin Pharmacol Ther"},{"key":"1289_CR27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","volume":"343","author":"WS Colucci","year":"2000","unstructured":"Colucci WS, Elkayam U, Horton DP (2000) Intravenous nesritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med 343:246\u2013253","journal-title":"N Engl J Med"},{"issue":"2","key":"1289_CR28","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. (2006) Vasopressin-2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2):F273\u2013F278","journal-title":"Am J Physiol Renal Physiol"},{"key":"1289_CR29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","volume":"6","author":"G Cotter","year":"2004","unstructured":"Cotter G, Kaluski E, Stangl K, et al. (2004) The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6:601\u2013609","journal-title":"Eur J Heart Fail"},{"key":"1289_CR30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.91.3.691","volume":"91","author":"I Crozier","year":"1995","unstructured":"Crozier I, Ikram H, Awan N, et al. (1995) Losartan in heart failure: hemodynamic effects and tolerability. Circulation 91:691\u2013697","journal-title":"Circulation"},{"key":"1289_CR31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/01.CIR.92.6.1387","volume":"92","author":"AH Danser","year":"1995","unstructured":"Danser AH, Schalekamp MA, Bax WA, et al. (1995) Angiotensin converting enzyme in the human heart. Effect of the deletion\/insertion polymorphism. Circulation 92: 1387\u20131388","journal-title":"Circulation"},{"key":"1289_CR32","unstructured":"Data on file. Bosentan use in pediatrics. Actelion Pharmaceuticals, South San Francisco, CA"},{"key":"1289_CR33","unstructured":"Data on file. Use in pediatrics. Pfizer Pharmaceuticals Group, Kalamazoo, MI"},{"key":"1289_CR34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0773.1998.tb01572.x","volume":"82","author":"M Gasparo de","year":"1988","unstructured":"de Gasparo M, Levens N (1988) Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol 82:257\u2013271","journal-title":"Pharmacol Toxicol"},{"key":"1289_CR35","doi-asserted-by":"crossref","first-page":"94A","DOI":"10.1016\/S0895-7061(97)91056-6","volume":"11","author":"JA Delyani","year":"1998","unstructured":"Delyani JA, Myles K, Funder J (1998) Eplerenone (SC 66110), a highly selective aldosterone antagonist [Abstract]. Am J Hypertens 11:94A","journal-title":"Am J Hypertens"},{"key":"1289_CR36","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","volume":"281","author":"JA Delyani","year":"2001","unstructured":"Delyani JA, Robinson EL, Rudolph AE (2001) Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 281:H647\u2013H654","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1289_CR37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1527-3466.2001.tb00064.x","volume":"19","author":"JA Delyani","year":"2001","unstructured":"Delyani JA, Rocha R, Cook CS, et al. (2001) Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 19:185\u2013200","journal-title":"Cardiovasc Drug Rev"},{"key":"1289_CR38","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","volume":"99","author":"A Deswal","year":"1999","unstructured":"Deswal A, Bozkurt B, Seta Y, et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Entanercept) in patients with advanced heart failure. Circulation 99:3224\u20133226","journal-title":"Circulation"},{"key":"1289_CR39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/01.HYP.28.1.98","volume":"28","author":"JL Dieaguez-Lucena","year":"1996","unstructured":"Dieaguez-Lucena JL, Aranda-Lara P, Ruiz-Galdoh M, et al. (1996) Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension 28:98\u2013103","journal-title":"Hypertension"},{"key":"1289_CR40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejheart.2004.10.015","volume":"7","author":"I Edes","year":"2005","unstructured":"Edes I, Gasior Z, Wita K (2005) Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 7:631\u2013639","journal-title":"Eur J Heart Fail"},{"key":"1289_CR41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.RES.77.1.107","volume":"77","author":"I Edes","year":"1995","unstructured":"Edes I, Kiss E, Kitada Y et al. (1995) Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77:107\u2013131","journal-title":"Circ Res"},{"key":"1289_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","volume":"62","author":"BS Edwards","year":"1988","unstructured":"Edwards BS, Zimmerman RS, Schwab TR, et al. (1988) Atrial stretch, not pressure, is the prinicipal determinant controlling the release of atrial natriuretic factor. Circ Res 62:191\u2013195","journal-title":"Circ Res"},{"key":"1289_CR43","first-page":"928","volume":"17","author":"D Ellis","year":"2004","unstructured":"Ellis D, Moritz ML, Vats A, Janosky JE (2004) Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens 17:928\u2013935","journal-title":"Am J Hypertens"},{"key":"1289_CR44","unstructured":"Eplerenone Package insert (2003) Pfizer Pharmaceuticals Group, Kalamazoo, MI"},{"key":"1289_CR45","unstructured":"Etanercept (Enbrel). Data on File. Amgen Corporation, Seattle, WA"},{"key":"1289_CR46","unstructured":"Etanercept (Enbrel) (2002) Package insert. Amgen Corporation, Seattle, WA"},{"key":"1289_CR47","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","volume":"344","author":"DV Exner","year":"2001","unstructured":"Exner DV, Dries DL, Domanski MJ, et al. (2001) Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344:1351\u20131357","journal-title":"N Engl J Med"},{"key":"1289_CR48","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.healun.2003.09.030","volume":"23","author":"B Feingold","year":"2004","unstructured":"Feingold B, Law YM (2004) Use of nesiritide in pediatric patients with congestive heart failure. J Heart Lung Transplant 23:1455\u20131459","journal-title":"J Heart Lung Transplant"},{"key":"1289_CR49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00129784-200404010-00002","volume":"4","author":"AM Feldman","year":"2004","unstructured":"Feldman AM, McTiernan C (2004) Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 4:11\u201319","journal-title":"Am J Cardiovasc Drugs"},{"key":"1289_CR50","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/hc5001.101749","volume":"104","author":"S Fichtischerer","year":"2001","unstructured":"Fichtischerer S, Rossig L, Breuer S, et al. (2001) Tumor necrosis factor antagonism with Etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104:3023\u20133025","journal-title":"Circulation"},{"key":"1289_CR51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coat AJ, et al. (2005) SENIORS Investigators. Randomized trial to determine the effect of nebivolol an mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215\u2013252","journal-title":"Eur Heart J"},{"key":"1289_CR52","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JGF, Just H, et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LiDO study): a randomized double-blind trial. Lancet 360:196\u2013202","journal-title":"Lancet"},{"key":"1289_CR53","doi-asserted-by":"crossref","first-page":"80G","DOI":"10.1016\/j.amjcard.2005.07.025","volume":"96","author":"F Follath","year":"2005","unstructured":"Follath F, Franco F, Cardoso JS (2005) European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 96:80G\u201385G","journal-title":"Am J Cardiol"},{"key":"1289_CR54","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-8703(99)70060-8","volume":"138","author":"GS Francis","year":"1999","unstructured":"Francis GS (1999) Is there still a future neutral endopeptidase inhibitors? Am Heart J 138:1007\u20131008","journal-title":"Am Heart J"},{"key":"1289_CR55","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00005344-200405000-00005","volume":"439","author":"HJ Garban","year":"2004","unstructured":"Garban HJ, Buga GM, Ignarro LJ (2004) Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanim of therapeutic vasorelaxation. J Cardiovasc Pharmacol 439:638\u2013644","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR56","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107:2690\u20132696","journal-title":"Circulation"},{"key":"1289_CR57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","volume":"11","author":"M Gheorghiade","year":"2005","unstructured":"Gheorghiade M, Orlandi C, Burnett JC, et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 11:260\u2013269","journal-title":"J Card Fail"},{"key":"1289_CR58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S1047951103000672","volume":"13","author":"A Giardini","year":"2003","unstructured":"Giardini A, Formigari R, Bronzetti G, et al. (2003) Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. Cardiol Young 13:333\u2013336","journal-title":"Cardiol Young"},{"key":"1289_CR59","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","volume":"101","author":"MM Givertz","year":"2000","unstructured":"Givertz MM, Colucci WS, LeJemtel TH, et al. (2000) Acute endothelin a receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101:2922\u20132927","journal-title":"Circulation"},{"key":"1289_CR60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0002-9149(86)90065-2","volume":"58","author":"SR Goldsmifh","year":"1986","unstructured":"Goldsmith SR, Francis GS, Cowley AW Jr (1986) Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58:295\u2013299","journal-title":"Am J Cardiol"},{"key":"1289_CR61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al. (2003) CHARM Investigators and Committees. Effects of candesartan patients with chronic heart failure and preserved left-ventricularjejection fraction: the CHARM-Preserved Trial. Lancet 362:777\u2013781","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1289_CR62","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00005344-199506261-00003","volume":"26","author":"H Haikala","year":"1995","unstructured":"Haikala H, Linden I-B (1995) Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1): S10\u2013S19","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR63","doi-asserted-by":"crossref","first-page":"4(1)","DOI":"10.1016\/S0002-9149(99)00310-0","volume":"83","author":"V Harjola","year":"1999","unstructured":"Harjola V, Peuhkurinen K, Nieminen M, et al. (1999) Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 83:4(l)\u20138(l)","journal-title":"Am J Cardiol"},{"key":"1289_CR64","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/sj.bjp.0702167","volume":"125","author":"A Heinemann","year":"1998","unstructured":"Heinemann A, Horina G, Stauber RE, et al. (1998) Lack of effect of a selective vasopressin V1a receptor anatagonist SR 49059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed. Br J Pharmacol 125:1120\u20131127","journal-title":"Br J Pharvacol"},{"issue":"Suppl 2","key":"1289_CR65","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1055\/s-2004-830452","volume":"53","author":"M Hoch","year":"2005","unstructured":"Hoch M, Netz H (2005) Heart failure in pediatric patients. Thorac Cardiovasc Surg 53(Suppl 2):S129\u2013S134","journal-title":"Thorac Cardiovasc Surg"},{"key":"1289_CR66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00246-001-0026-y","volume":"23","author":"MS Horenstein","year":"2002","unstructured":"Horenstein MS, Ross RD, Singh TP, Epstein ML (2002) Carvedilol reverses elevated pulmonary vascular resistance in a child with dilated cardiomyopathy. Pediatr Cardiol 23:100\u2013102","journal-title":"Pediatr Cardiol"},{"key":"1289_CR67","first-page":"F286","volume":"264","author":"M Horiuchi","year":"1993","unstructured":"Horiuchi M, Nishiyana H, Hama J, et al. (1993) Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 264:F286\u2013F291","journal-title":"Am J Physiol"},{"key":"1289_CR68","doi-asserted-by":"crossref","first-page":"9(l)","DOI":"10.1016\/S0002-9149(99)00311-2","volume":"83","author":"J Hosenpud","year":"1999","unstructured":"Hosenpud J, Levosimendan, (1999) a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 83:9(l)\u201311(l)","journal-title":"Am J Cardiol"},{"key":"1289_CR69","unstructured":"Infliximab (Remicade) Package insert (2003) Centocor, Malvern, PA"},{"key":"1289_CR70","first-page":"1531","volume":"287","author":"Intravenous","year":"2002","unstructured":"Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial (2002) J Am Med Assoc 287:1531\u20131540","journal-title":"J Am Med Assoc"},{"key":"1289_CR71","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1172\/JCI114893","volume":"86","author":"H Itoh","year":"1990","unstructured":"Itoh H, Pratt RE, Dzau VJ (1990) Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86:1690\u20131697","journal-title":"J Clin Invest"},{"key":"1289_CR72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/phgs.5.3.331.29830","volume":"5","author":"KK Jain","year":"2004","unstructured":"Jain KK (2004) Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 5:331\u2013336","journal-title":"Pharmacogenomics"},{"key":"1289_CR73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0014-2999(98)00907-8","volume":"366","author":"PM Janssen","year":"1999","unstructured":"Janssen PM, Zeitz O, Hasenfuss G (1999) Transient and sustained impacts of hydroxy radicals on sarcoplasmic reticulum function: the protective effects of nebivolol. Eur J Pharmacol 366:223\u2013232","journal-title":"Eur J Pharmacol"},{"key":"1289_CR74","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0735-1097(01)01775-2","volume":"39","author":"P Jong","year":"2002","unstructured":"Jong P, Demers C, McKelvie RS, Liu PP (2002) Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 39:463\u2013470","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR75","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","volume":"335","author":"JC Kahn","year":"1990","unstructured":"Kahn JC, Patey M, Dubois-Rande JL, et al. (1990) Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 335:118\u2013119","journal-title":"Lancet"},{"key":"1289_CR76","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0735-1097(02)02708-0","volume":"41","author":"E Kaluski","year":"2003","unstructured":"Kaluski E, Kobrin I, Zimlichman R, et al. (2003) RITZ-5: randomized intravenous tezosentan (an endothelin A\/B antagonist) for the treatmert of pulmonary edema. J Am Coll Cardiol 41:204\u2013210","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR77","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","volume":"26","author":"DM Kaye","year":"1995","unstructured":"Kaye DM, Lefkovits J, Jennings GL, et al. (1995) Adverse consequences of high sympathetic nervous activity in the failing heart. J Am Coll Cardiol 26:1257\u20131263","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00008480-199504000-00018","volume":"7","author":"GL Kearns","year":"1995","unstructured":"Kearns GL (1995) Pharmacogenetics and development: are infants and increased risk for adverse outcomes? Curr Opin Pediatr 7:220\u2013233","journal-title":"Curr Opin Pediatr"},{"key":"1289_CR79","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1067\/mai.2000.109419","volume":"106","author":"GL Kearns","year":"2000","unstructured":"Kearns GL (2000) Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 106:S128\u2013S138","journal-title":"J Allergy Clin Immunol"},{"key":"1289_CR80","first-page":"509","volume":"273","author":"S Kim","year":"1995","unstructured":"Kim S, Ohta K, Hamaguchi A, et al. (1995) Angiotensin II type 1 receptor antagonist inhibits gene expression of transforming growth factor-\u00df1 and extracellular matrix in cardiac and vascular tissue of hypertensive rats. J Pharmacol Exp Ther 273:509\u2013551","journal-title":"J Pharmacol Exp Ther"},{"key":"1289_CR81","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"246","author":"W Kiowski","year":"1995","unstructured":"Kiowski W, Sutsch G, Hunziker P, et al. (1995) Evidence for endothelin-l-mediated vasoconstriction in severe chronic heart failure. Lancet 246:732\u2013736","journal-title":"Lancet"},{"key":"1289_CR82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002042001005","volume":"42","author":"M Kivikko","year":"2002","unstructured":"Kivikko M, Antila S, Eha J, et al. (2002) Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42:43\u201351","journal-title":"J Clin Pharmacol"},{"key":"1289_CR83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5414\/CPP40465","volume":"40","author":"M Kivikko","year":"2003","unstructured":"Kivikko M, Antila S,Eha J, et al. (2003) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40:465\u2013471","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1289_CR84","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.0000043245.00859.11","volume":"107","author":"M Kivikko","year":"2003","unstructured":"Kivikko M, Lehtonen L, Colucci W, et al. (2003) Sustained hemodynamic effects of intravenous levosimendan. Circulation 107:81\u201386","journal-title":"Circulation"},{"key":"1289_CR85","doi-asserted-by":"crossref","first-page":"23932","DOI":"10.1074\/jbc.274.34.23932","volume":"274","author":"Q Kleerekoper","year":"1999","unstructured":"Kleerekoper Q, Putkey JA (1999) Drug binding to cardiac troponin C. J Biol Chem 274:23932\u201323939","journal-title":"J Biol Chem"},{"key":"1289_CR86","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/01.CIR.86.4.1081","volume":"86","author":"KJ Koller","year":"1992","unstructured":"Koller KJ, Goeddel DV (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86:1081\u20131088","journal-title":"Circulation"},{"key":"1289_CR87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0014-2999(01)01350-4","volume":"428","author":"D Kopustinskiene","year":"2001","unstructured":"Kopustinskiene D, Pollesello P, Saris N (2001) Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 428:311\u2013314","journal-title":"Eur J Pharmacol"},{"key":"1289_CR88","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.bcp.2004.05.018","volume":"68","author":"DM Kopustinskiene","year":"2004","unstructured":"Kopustinskiene DM, Pollesello P, Saris NE (2004) Potassium-specific effecrs of levosimendan on heart mitochondria. Biochem Pharmacol 68:807\u2013821","journal-title":"Biochem Pharmacol"},{"key":"1289_CR89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00016349808565802","volume":"77","author":"A Kostrzewska","year":"1998","unstructured":"Kostrzewska A, Laudanski T, Steinwall M, et al. (1998) Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances. Acta Obstet Gynecol Scand 77:3\u20137","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1289_CR90","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1067\/mhj.2002.121265","volume":"143","author":"S Laer","year":"1998","unstructured":"Laer S, Mir TS, Behn F, Eiselt M, et al. (1998) Carvedilol therapy in pediatric patients with congestive heari failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143:916\u2013922","journal-title":"Am Heart J"},{"key":"1289_CR91","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjcard.2004.10.014","volume":"95","author":"YM Law","year":"2005","unstructured":"Law YM, Keller BB, Feingold BM, Boyle GJ (2005) Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 95:474\u2013478","journal-title":"Am J Cardiol"},{"key":"1289_CR92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0031-3955(05)70463-6","volume":"44","author":"JS Leeder","year":"1997","unstructured":"Leeder JS, Kearns GL (1997) Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 44:55\u201377","journal-title":"Pediatr Clin North Am"},{"key":"1289_CR93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00003088-200443030-00003","volume":"43","author":"LA Lehtonen","year":"2004","unstructured":"Lehtonen LA, Antila S, Pentikainen PJ (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43:187\u2013203","journal-title":"Clin Pharmacokinet"},{"key":"1289_CR94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-2999(03)01423-7","volume":"464","author":"I Lepran","year":"2003","unstructured":"Lepran I, Papp J (2003) Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats. Eur J Pharmacol 464:171\u2013176","journal-title":"Eur J Pharmacol"},{"key":"1289_CR95","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/jmcc.1999.1093","volume":"32","author":"J Levijoki","year":"2000","unstructured":"Levijoki J, Piero P, Kaivola J, et al. (2000) Further evidence for the cardiac troponin C mediated calcium sensitization by levosimedan: structure\u2013response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 32:479\u2013491","journal-title":"J Mol Cell Cardiol"},{"key":"1289_CR96","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine B, Kalman H, Mayer L, et al. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Eng J Med 323:236\u2013241","journal-title":"N Eng J Med"},{"key":"1289_CR97","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/clpt.1994.177","volume":"56","author":"J Lilleberg","year":"1994","unstructured":"Lilleberg J, Antila S, Karlsson M, et al. (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 56:554\u2013563","journal-title":"Clin Pharmacol Ther"},{"key":"1289_CR98","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/euhj.1997.0806","volume":"19","author":"J Lilleberg","year":"1998","unstructured":"Lilleberg J, Nieminen S, Akkila J, et al. (1998) Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19:660\u2013668","journal-title":"Eur Heart J"},{"key":"1289_CR99","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1042\/cs0890481","volume":"89","author":"JJ Liu","year":"1995","unstructured":"Liu JJ, Chen JR, Buxton BB, et al. (1995) Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin Via receptor antagonist, on human arterial coronary bypass graft. Clin Sci (Londn) 89:481\u2013485","journal-title":"Clin Sci (Londan)"},{"key":"1289_CR100","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s002109900187","volume":"361","author":"C Loichot","year":"2000","unstructured":"Loichot C, Cazaubon C, De Jong W, et al. (2000) Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmeidebergs Arch Pharmacol 361:319\u2013326","journal-title":"Naunyn Schmeidebergs Arch Pharmacol"},{"key":"1289_CR101","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","volume":"106","author":"TF Luscher","year":"2002","unstructured":"Luscher TF, Enseleit F, Pacher R, et al. (2002) Hemodynamic and neurohormonal effects of selective endothelin A (ET A ) receptor blockade in chronic heart failure. Circulation 106:2666\u20132672","journal-title":"Circulation"},{"key":"1289_CR102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00392-004-0053-9","volume":"93","author":"YC Luther","year":"2004","unstructured":"Luther YC, Schulze-Neick I, Stiller B, et al. (2004) Levosimendan\u2013long-term inodilation in an infant with myocardial infarction. Z Kardiol 93:234\u2013239","journal-title":"Z Kardiol"},{"key":"1289_CR103","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","volume":"40","author":"AP Maggioni","year":"2002","unstructured":"Maggioni AP, Anand I, Gottlieb SO, et al. Val-HeFT investigators (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40:1414\u20131421","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR104","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.PCC.0000164634.58297.9A","volume":"6","author":"WT Mahle","year":"2005","unstructured":"Mahle WT, Cuadrado AR, Kirshborn PM, Kanter KR, Simsic JM (2005) Nesiritide in infants and children with congestive heart failure. Pediatr Crit Care Med 6:543\u2013 546","journal-title":"Pediatr Crit Care Med"},{"key":"1289_CR105","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/01.CIR.94.12.3184","volume":"94","author":"LS Marcus","year":"1996","unstructured":"Marcus LS, Hart D, Packer M, et al. (1996) Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation 94:3184\u20133189","journal-title":"Circulation"},{"key":"1289_CR106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","volume":"7","author":"D Marez","year":"1997","unstructured":"Marez D, Legrand M, Sabbagh N, et al. (1997) Ploymorphism of the cytochrome P450 CYP2D6 gene in a European papulation: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193\u2013202","journal-title":"Pharmacogenetics"},{"key":"1289_CR107","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00005344-200207000-00014","volume":"40","author":"MR Marino","year":"2002","unstructured":"Marino MR, Vachharajani NN (2002) Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol 40:112\u2013122","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR108","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0885066604263828","volume":"19","author":"J Marshall","year":"2004","unstructured":"Marshall J, Berkenbosch JW, Russo P, Tobias JD (2004) Preliminary experience with nesiritide in the pediatric population. J Intensive Care Med 19:164\u2013170","journal-title":"J Intensive Care Med"},{"key":"1289_CR109","first-page":"521","volume":"12","author":"J Martin","year":"2001","unstructured":"Martin J, Krum H (2001) Eplerenone (GD Searle & Co.). Curr Opin Invest Drugs 12:521\u2013524","journal-title":"Curr Opin Invest Drugs"},{"key":"1289_CR110","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0895-7061(94)00196-I","volume":"8","author":"BJ Materson","year":"1995","unstructured":"Materson BJ, Reda DJ, Cushman WC (1995) Department of Veterans Affairs single drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 8:189\u2013192","journal-title":"Am J. Hypertens"},{"key":"1289_CR111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1997.00545.x","volume":"43","author":"G Mcdowell","year":"1997","unstructured":"McDowell G, Coutie W, Shaw C, et al. (1997) The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmgcol 43:329\u2013332","journal-title":"Br J Clin Pharmgcol"},{"key":"1289_CR112","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"!McKelvie RS, Yusuf S, Pericak D, et al; RESOLVD pilot study investigators (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100:1056\u20131064","journal-title":"Circulation"},{"key":"1289_CR113","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, CHARM et al. investigators and committee (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772\u2013776","journal-title":"Lancet"},{"key":"1289_CR114","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1161\/01.CIR.103.12.1644","volume":"103","author":"DM McNamara","year":"2001","unstructured":"McNamara DM, Holubkov R, Janosko K, et al. (2001) Pharmacogenetic interactions between beta-blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103:1644\u20131648","journal-title":"Circulation"},{"key":"1289_CR115","unstructured":"Micromedex. Spironolactone\u2014drug evaluation. Online healthcare series. (2003, October 12) Available at http:\/\/www. micromedex.com\/products\/hcsonline\/"},{"key":"1289_CR116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0735-1097(99)00184-9","volume":"34","author":"RM Mills","year":"1999","unstructured":"Mills RM, LeJemtel TH, Horton DP, et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure. J Am Coll Cardiol 34:155\u2013162","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR117","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1542\/peds.110.6.e76","volume":"110","author":"TS Mir","year":"2002","unstructured":"Mir TS, Marohn S, Laer S, et al. (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76","journal-title":"Pediatrics"},{"key":"1289_CR118","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","volume":"23","author":"V Moiseyev","year":"2002","unstructured":"Moiseyev V, Poder P, Andrejevs N, et al. (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23:1422\u20131432","journal-title":"Eur Heart J"},{"key":"1289_CR119","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00003246-200204000-00018","volume":"30","author":"S Mou","year":"2002","unstructured":"Mou S, Haudek S, Lequier L, et al. (2002) Myocardial inflammatory activation in children with congenital heart disease. Crit Care Med 30:827\u2013832","journal-title":"Crit Care Med"},{"key":"1289_CR120","unstructured":"National Institutes of Health Clinical Trials Web page, http:\/\/www.clinicaltrials.gov (accessed 2004, April 30)"},{"key":"1289_CR121","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0735-1097(00)00961-X","volume":"36","author":"M Nieminen","year":"2000","unstructured":"Nieminen M, Akkila J, Hasenfuss G, et al. (2000) Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903\u20131912","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR122","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00005344-199908000-00007","volume":"34","author":"N Nijwahan","year":"1999","unstructured":"Nijwahan N, Nicolosi A, Montgomery M, et al. (1999) Levosimendan enchances cardiac performance after cardio- pulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34:219\u2013228","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR123","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1388-9842(98)00003-8","volume":"1","author":"DB Northridge","year":"1999","unstructured":"Northridge DB, Currie PF, Newby DE, et al. (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Failure 1:67\u201372","journal-title":"Eur J Heart Failure"},{"key":"1289_CR124","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-8703(99)70082-7","volume":"138","author":"DB Northridge","year":"1999","unstructured":"Northridge DB, Newby DE, Rooney E, et al. (1999) Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 138:1149\u20131157","journal-title":"Am Heart J"},{"issue":"4 pt 2","key":"1289_CR125","first-page":"H1824","volume":"273","author":"M Obayashi","year":"1997","unstructured":"Obayashi M, Yano M, Kohno M, et al. (1997) Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 273 (4 pt 2):H1824\u2013H1831","journal-title":"Am J Physiol"},{"key":"1289_CR126","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(03)00194-3","volume":"41","author":"CM O\u2019Conner","year":"2003","unstructured":"O\u2019Conner CM, Gattis WA, Adams KF, et al. (2003) Tezosentan in patients with acute heart failure and acute coronary syndromes. Results of the Randomized Intravenous Tezosentan Study (RITZ-4). J Am Coll Cardiol 41:1452\u20131457","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR127","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0002-8703(99)70081-5","volume":"138","author":"CM O\u2019Conner","year":"1999","unstructured":"O\u2019Conner CM, Gattis WA, Gheorghiade M, et al. (1999) A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 138:1140\u20131148","journal-title":"Am Heart J"},{"key":"1289_CR128","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/01.CIR.0000034444.31846.F4","volume":"106","author":"H Ooi","year":"2002","unstructured":"Ooi H, Colucci WS, Givertz MM (2002) Endothelin mediates increased plumonary vascular tone in patients with failure. Circulation 106:1618\u20131621","journal-title":"Circulation"},{"key":"1289_CR129","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1071-9164(03)00532-3","volume":"9","author":"M Packer","year":"2003","unstructured":"Packer M, Colucci WS, Fisher L, et al. (2003) Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure: result with levosimendan in the REVIVE-1 study [Abstract]. J Card Failure 9:S61","journal-title":"J Card Failure"},{"key":"1289_CR130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1025331617233","volume":"17","author":"J Pataricza","year":"2003","unstructured":"Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG (2003) Functional channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17:115\u2013121","journal-title":"Cardiovasc Drugs Ther"},{"key":"1289_CR131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1592\/phco.23.4.451.32116","volume":"23","author":"JH Patterson","year":"2003","unstructured":"Patterson JH, Rodgers JE (2003) Expanding role of beta-blockade in the management of chronic heart failure. Pharmacotherapy 23:451\u2013459","journal-title":"Pharmacotherapy"},{"key":"1289_CR132","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0008-6363(99)00151-0","volume":"43","author":"WJ Paulus","year":"1999","unstructured":"Paulus WJ, Shah AM (1999) NO and cardiac diastolic function. Cardiovasc Res 43:595\u2013606","journal-title":"Cardiovasc Res"},{"key":"1289_CR133","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1042\/CS103S249S","volume":"103","author":"S Philipp","year":"2002","unstructured":"Philipp S, Monti J, Pagel I, et al. (2002) Treatment with darusentan over 21 days improved cGMP generation in patients with chronic heart failure. Clin Sci 103:2495\u20132535","journal-title":"Clin Sci"},{"key":"1289_CR134","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial\u2014The losartan heart failure survival study ELITE II. Lancet 355:1582\u20131587","journal-title":"Lancet"},{"key":"1289_CR135","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reicheck N, Willnebrock R, et al. (2003) Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation 108:1831\u20131838","journal-title":"Circulation"},{"issue":"part 2","key":"1289_CR136","doi-asserted-by":"crossref","first-page":"23A","DOI":"10.1016\/S0895-7061(02)02332-4","volume":"15","author":"B Pitt","year":"2002","unstructured":"Pitt B, Reichek N, Metscher B, et al. (2002) Efficacy and safety of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in patients with left ventricular hypertrophy [Abstract]. Am J Hypertens 15 (part 2):23A","journal-title":"Am J Hypertens"},{"key":"1289_CR137","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, for the EPHESUS study group et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"1289_CR138","unstructured":"Pitt B, Roniker B (1999) Eplerenone, a novel selective aldosterone receptor antagonist (SARA) dose finding study in patients with heart failure [Abstract]. J Am Coll Cardiol 33S188A\u201333S189A"},{"key":"1289_CR139","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA, et al. (1997) Randomised trial of losartan versus captopril in patients greater than 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349:747\u2013752","journal-title":"Lancet"},{"key":"1289_CR140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/CS20020046","volume":"103","author":"VF Puddy","year":"2002","unstructured":"Puddy VF, Amirmansour C, Williams AF, Singer DR (2002) Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (London) 103:75\u201377","journal-title":"Clin Sci (London)"},{"issue":"2 pt 2","key":"1289_CR141","first-page":"801","volume":"37","author":"L F Quashning Ruschitzka","year":"2001","unstructured":"Quashning L Ruschitzka F, Shaw S, et al. (2001) Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2 pt 2):801\u2013805","journal-title":"Hypertesion"},{"key":"1289_CR142","first-page":"308","volume":"40","author":"WO Roberston","year":"1998","unstructured":"Roberston WO (1998) Chemicals, children, and research $\u2019s. Vet Hum Toxicol 40:308\u2013309","journal-title":"Vet Hum Toxicol"},{"issue":"1 pt 2","key":"1289_CR143","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, et al. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33(1 pt 2) 232\u2013237","journal-title":"Hypertension"},{"key":"1289_CR144","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT, Kifor I, et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871\u20133878","journal-title":"Endocrinology"},{"issue":"6 pt 2","key":"1289_CR145","first-page":"H2468","volume":"226","author":"HA Rockman","year":"1994","unstructured":"Rockman HA, Wachorst SP, Mao L, Ross J Jr (1994) ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 226(6 pt 2):H2468\u2013H2475","journal-title":"Am J Physiol"},{"key":"1289_CR146","first-page":"995","volume":"30","author":"B Roniker","year":"1997","unstructured":"Roniker B (1997) Eplerenone, a selective antagonist of the aldosterone receptor [Abstract]. Hypertension 30:995","journal-title":"Hypertension"},{"key":"1289_CR147","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9149(87)91118-0","volume":"59","author":"RD Ross","year":"1987","unstructured":"Ross RD, Daniels SR, Schwartz DC, et al. (1987) Plasma norepinephrine levels in infants and childern with congestive heart failure. Am J Cardiol 59:911\u2013914","journal-title":"Am J Cardiol"},{"key":"1289_CR148","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JU MA Rouleau Pfeffer","year":"2000","unstructured":"Rouleau JU Pfeffer MA, Stewart DJ, et al. (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 356:615\u2013620","journal-title":"Lancet"},{"key":"1289_CR149","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.healun.2003.07.025","volume":"23","author":"P Rusconi","year":"2004","unstructured":"Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. (2004) Carvedilol in children with cardiomyopthy: 3-year experience at a single institution. J Heart Lung Transplant 23:832\u2013838","journal-title":"J Heart Lung Transplant"},{"key":"1289_CR150","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","volume":"293","author":"JD Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis randomized controlled trials. J Am Med Assoc 293:1900\u20131905","journal-title":"J Am Med Assoc"},{"key":"1289_CR151","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","volume":"111","author":"JD Sackner-Bernstein","year":"2005","unstructured":"Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487\u20131491","journal-title":"Circulation"},{"key":"1289_CR152","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/00912700122010645","volume":"41","author":"A Sakarcan","year":"2001","unstructured":"Sakarcan A, Tenney F, Wilson JT, et al. (2001) The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 41:742\u2013749","journal-title":"J Clin Pharmacol"},{"key":"1289_CR153","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/00004872-199612000-00003","volume":"14","author":"M Sasaki","year":"1996","unstructured":"Sasaki M, Oki T, Iuchi A, et al. (1996) Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential: M-mode and pulsed Doppler echocardiographic studies. J Hypertens 14:1403\u20131408","journal-title":"J Hypertens"},{"key":"1289_CR154","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1006\/jmcc.1998.0677","volume":"30","author":"S Sato","year":"1998","unstructured":"Sato S, Hassan Talukder M, Sugawara H, et al. (1998) Effects of levosimendan on myocardial contractility and Ca++ transients in aequorin-loaded right ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30:1115\u20131128","journal-title":"J Mol Cell Cardiol"},{"key":"1289_CR155","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mhj.2001.116760","volume":"142","author":"C Schalcher","year":"2001","unstructured":"Schalcher C, Cotter G, Reisin L, et al. (2001) The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 142:340\u2013349","journal-title":"Am Heart J"},{"key":"1289_CR156","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/01.TP.0000137790.63159.48","volume":"78","author":"I Schulze-Neick","year":"2004","unstructured":"Schulze-Neick I, Luther YC, Ewert P, et al. (2004) End stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart\u2013lung transplantation. Transplantation 78:1237\u20131238","journal-title":"Transplantation"},{"key":"1289_CR157","unstructured":"Scios, lnc. (2001) NDA 20-920: Natrecor (nesiritide) Cardiovascular and Renal Drugs Advisory Committee briefing document. Food and Drug Administration, Rockville, MD"},{"key":"1289_CR158","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/00004872-200207000-00024","volume":"20","author":"G Segarra","year":"2002","unstructured":"Segarra G, Medina P, Vila JM, et al. (2002) Increased contraction to noradrenaline by vasopressin in human renal arteries. J Hypertension 20:1373\u20131379","journal-title":"J Hypertension"},{"key":"1289_CR159","first-page":"254","volume":"5","author":"R Sehra","year":"2003","unstructured":"Sehra R, Underwood K (2003) Nesiritide improves urine output in severely ill pediatric patients awaiting heart transplant without severe hypotension. J Card Failure 5:254","journal-title":"J Card Failure"},{"key":"1289_CR160","first-page":"633","volume":"47","author":"G Serradeil Le-Gal","year":"1994","unstructured":"Serradeil Le-Gal G, Bourrie B, Raufaste D, et al. (1994) Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and mitogenic actiyity of vasopressin on Swiss 3T3 cells. Biochem Pharmacol 47:633\u2013641","journal-title":"Biochem Pharmacol"},{"issue":"1 pt 2","key":"1289_CR161","first-page":"H404","volume":"268","author":"C Serradeil Le-Gal","year":"1995","unstructured":"Serradeil Le-Gal C, Herbert JM, Delisse C, et al. (1995) Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am J Physiol 268(1 pt 2):H404\u2013H410","journal-title":"Am J Physiol"},{"key":"1289_CR162","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1472-8206.1995.tb00260.x","volume":"9","author":"C Serradeil-Le Gal","year":"1995","unstructured":"Serradeil-Le Gal C, Villanova G, Boutin M, et al. (1995) Effects of SR 49059, a non-peptide antagonist of vasopressin-induced coronary vasoconstriction in conscious rabbits. Fundam Clin Pharmacol 9:17\u201324","journal-title":"Fundam Clin Pharmacol"},{"key":"1289_CR163","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","volume":"92","author":"C Serradeil-Le Gal","year":"1993","unstructured":"Serradeil-Le Gal C, Wagnon J, Garcia C, et al. (1993) Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 92:224\u2013231","journal-title":"J Clin Invest"},{"key":"1289_CR164","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199103000-00015","volume":"17","author":"AA Seymour","year":"1991","unstructured":"Seymour AA, Swerdel JN, Abboa-Offei B (1991) Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 17:456\u2013465","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1058-9813(00)00062-X","volume":"12","author":"R. Shaddy","year":"2000","unstructured":"Shaddy R (2000) Beta-adrenergic blockers in the treatment of pediatric heart failure. Prog Pediatr Cardiol 12:113\u2013118","journal-title":"Prog Pediatr Cardiol"},{"key":"1289_CR166","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1053-2498(98)00030-8","volume":"18","author":"RE Shaddy","year":"1999","unstructured":"Shaddy RE, Tani LY, Gidding SS, et al. (1999) Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 18:269\u2013274","journal-title":"J Heart Lung Transplant"},{"key":"1289_CR167","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-8703(98)70176-0","volume":"136","author":"RE Shaddy","year":"1998","unstructured":"Shaddy RE (1998) Beta-blocker therapy in young children with congestive heart failure under consideration for heart transplantation. Am Heart J 136:19\u201321","journal-title":"Am Heart J"},{"issue":"2 pt 1","key":"1289_CR168","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amjhyper.2004.09.009","volume":"18","author":"S Shahinfar","year":"2005","unstructured":"Shahinfar S, Cano F, Soffer BA, et al. (2005) A double-blind, dose\u2013response study of losartan in hypertensive children. Am J Hypertens 18(2 pt 1):183\u2013190","journal-title":"Am J Hypertens"},{"key":"1289_CR169","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0735-1097(01)01818-6","volume":"39","author":"MA Silver","year":"2002","unstructured":"Silver MA, Horton DP, Ghali JK, et al. (2002) Effect of nesiritide versus dobutamine on short term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39:798\u2013803","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1289_CR170","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00246-003-0680-3","volume":"25","author":"JM Simsic","year":"2004","unstructured":"Simsic JM, Reddy VS, Kanter KR, Kirshbom PM, Forbess JM (2004) Use of nesiritide (human B-type natriuretic peptide) in infants following cardigc surgery. Pediatr Cardiol 25(6):668\u2013670","journal-title":"Pediatr Cardiol"},{"key":"1289_CR171","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1161\/01.CIR.102.18.2222","volume":"102","author":"M Slawsky","year":"2000","unstructured":"Slawsky M, Colucci W, Gottlieb S, et al. (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102:2222\u20132227","journal-title":"Circulation"},{"key":"1289_CR172","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1460-9592.2004.01398.x","volume":"15","author":"T Smith","year":"2005","unstructured":"Smith T, Rosen DA, Russo P, et al. (2005) Nesiritide during extracorporeal membrane oxygenation. Paediatr Anaesth 15:152\u2013157","journal-title":"Paediatr Anaesth"},{"issue":"suppl 2","key":"1289_CR173","doi-asserted-by":"crossref","first-page":"SII21","DOI":"10.1016\/S0140-6736(99)90253-2","volume":"354","author":"RL Smyth","year":"1999","unstructured":"Smyth RL, Weindling AM (1999) Research in children: ethical and scientific aspects. Lancet 354(suppl 2):SII21\u2013SII24","journal-title":"Lancet"},{"key":"1289_CR174","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ahj.2004.09.056","volume":"150","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Skali H, Bourgoun M, OVERTURE Investigators et al. (2005) Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 150:257\u2013262","journal-title":"Am Heart J"},{"key":"1289_CR175","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0735-1097(00)00649-5","volume":"35","author":"LE Speiker","year":"2000","unstructured":"Speiker LE, Mitrovic V, Noll G, et al. (2000) Acute hemodynamic and neurohormonal effects of selective ET A receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 35:1745\u20131752","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR176","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0735-1097(01)01210-4","volume":"37","author":"LE Spieker","year":"2001","unstructured":"Spieker LE, Noll G, Ruschitzka FT, Luscher TF (2001) Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 37:1493\u20131505","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR177","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1442-200X.2003.01716.x","volume":"45","author":"K Suda","year":"2003","unstructured":"Suda K, Matsumura M, Matsumoto M (2003) Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 45:249\u2013254","journal-title":"Pediatr Int"},{"key":"1289_CR178","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/332078a0","volume":"332","author":"T Sudoh","year":"1988","unstructured":"Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new natriuretic pepetide in porcine brain. Nature 332:78\u201381","journal-title":"Nature"},{"key":"1289_CR179","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s002280050699","volume":"55","author":"S Sundberg","year":"2000","unstructured":"Sundberg S, Lehtonen L (2000) Haemodynamic interactions between the novel calcium sensitizer levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmool 55:793\u2013799","journal-title":"Eur J Clin Pharmocl"},{"key":"1289_CR180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/BF00053029","volume":"10","author":"G Sutsch","year":"1997","unstructured":"Sutsch G, Bertel O, Kiowski W (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drug Ther 10:717\u2013725","journal-title":"Cardiovasc Drug Ther"},{"key":"1289_CR181","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","volume":"98","author":"G Sutsch","year":"1998","unstructured":"Sutsch G, Kiowski W, Yan XW, et al. (1998) Short term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98:2262\u20132268","journal-title":"Circulation"},{"key":"1289_CR182","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/PL00005139","volume":"357","author":"A Tahara","year":"1998","unstructured":"Tahara A, Saito M, Sugimoto T, et al. (1998) Pharmacologic characterization of YM078, a potent, nonpeptide human vasopressin V1A and Vz recept or antagonist. Naunyn Schmeidebergs Arch Pharmacol 357:63\u201369","journal-title":"Arch Pharmacol"},{"key":"1289_CR183","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(99)00004-7","volume":"368","author":"A Tahara","year":"1999","unstructured":"Tahara A, Saito M, Tsukada J, et al. (1999) Vasopressin increases vascular endothelial growth factor secretion from vascular smooth muscle cells. Eur J Pharmacol 368:89\u201394","journal-title":"Eur J Pharmacol"},{"key":"1289_CR184","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00005344-199712000-00010","volume":"30","author":"A Tahara","year":"1997","unstructured":"Tahara A, Tomura Y, Wada K, et al. (1997) Effect of YM087, a potent non-peptide vasopressin antogonist on vasopressin-induced hyperplasia and hypertrophy of cultured smooth-muscle cells. J Cardiovasc Pharmacol 30:759\u2013766","journal-title":"J Cardiovasc Pharmacol"},{"key":"1289_CR185","first-page":"301","volume":"282","author":"A Tahara","year":"1997","unstructured":"Tahara A, Tomura Y, Wada K, et al. (1997) Pharmacologic profile of YM087, a novel potent nonpeptide vasopressin VlA and V2 receptor antagonist, in vitro and vivo. J Pharmacol Exp Ther 282:301\u2013308","journal-title":"J Pharmacol Exp Ther"},{"key":"1289_CR186","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(97)00324-6","volume":"38","author":"A Tahara","year":"1998","unstructured":"Tahara A, Tomura Y, Wada K, et al. (1998) Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 38:198\u2013205","journal-title":"Cardiovasc Res"},{"key":"1289_CR187","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/rmed.2000.1005","volume":"95","author":"T Takahashi","year":"2001","unstructured":"Takahashi T, Yamaguchi E, Furya K, et al. (2001) The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Repir Med 95:130\u2013135","journal-title":"Repir Med"},{"key":"1289_CR188","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.HYP.25.2.170","volume":"25","author":"T Takeda","year":"1995","unstructured":"Takeda T, Miyamori I Yoneda T, et al. (1995) Production of aldosterone in isolated rat blood vessels. Hypertension 25:170\u2013173","journal-title":"Hypertension"},{"key":"1289_CR189","first-page":"2797","volume":"81","author":"T Takeda","year":"1996","unstructured":"akeda T, Miyamori I, Yoneda T, et al. (1996) Regulation of aldosterone synthase in human vascular endothelial cells by adrenocorticotropin. J Clin Endocrinol Metab 81:2797\u20132800","journal-title":"J Clin Endocrinol Metab"},{"key":"1289_CR190","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1442-200x.2004.01955.x","volume":"46","author":"H Tanaka","year":"2004","unstructured":"Tanaka H, Suzuki K, Nakahata T, et al. (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576\u2013579","journal-title":"Pediatr Int"},{"key":"1289_CR191","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1022190503351","volume":"16","author":"P Tassani","year":"2002","unstructured":"Tassani P, Schad H, Heimisch W, et al. (2002) Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetized pigs. Cardiovasc Drugs Ther 16:435\u2013441","journal-title":"Cardiovasc Drugs Ther"},{"key":"1289_CR192","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2005.07.033","volume":"10","author":"AL Taylor","year":"2005","unstructured":"Taylor AL, (2005)The African American Heart Failure Trial: a clinical trial Update. Am J Cardiol 10:44\u201348","journal-title":"Am J Cardiol"},{"key":"1289_CR193","first-page":"46","volume":"150","author":"JR Teerlink","year":"2005","unstructured":"Teerlink JR, McMurray JJ, Bourge RC, VERITAS Investigators (2005) Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Study (VERITAS). Am Heart J 150:46\u201353","journal-title":"AmHeart J"},{"key":"1289_CR194","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.HYP.34.6.1293","volume":"341","author":"M Thibonnier","year":"1999","unstructured":"Thibonnier M, Kilani A, Rahmann M, et al. (1999) Effects of the nonpeptide Vl vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 341:1293\u20131300","journal-title":"Hypertension"},{"key":"1289_CR195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1440-1681.1999.03045.x","volume":"26","author":"Tomura","year":"1999","unstructured":"Tomura Y, Tahara A, Tsukada, et al. (1999) Pharmacologic profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 26:399\u2013403","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1289_CR196","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1378\/chest.120.2.460","volume":"120","author":"G Torre-Amione","year":"2002","unstructured":"Torre-Amione G (2002) A pilot safety trial of prolonged (48 hour) infusion of the dual endothelin receptor antagonist tezosentan in patients with advanced heart failure. Chest 120:460\u2013466","journal-title":"Chest"},{"key":"1289_CR197","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","volume":"27","author":"G Torre-Amione","year":"1996","unstructured":"Torre-Amione G, Kapadia S, Benedict C, et al. (1996) Proinflammatory cytokine levels in depressed left ventricular ejection fraction: a report from the studies of ventricular dysfunction (SOLVD). J Am Coll Card 27:1201\u20131206","journal-title":"J Am Coll Card"},{"key":"1289_CR198","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1161\/01.CIR.103.7.973","volume":"103","author":"G Torre-Amione","year":"2001","unstructured":"Torre-Amione G, Young JB, Durand JB, et al. (2001) Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to class IV congestive heart failure. Circulation 103:973\u2013980","journal-title":"Circulation"},{"key":"1289_CR199","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.bjp.0704117","volume":"133","author":"J Tsukada","year":"2001","unstructured":"Tsukada J, Tahara A, Tomura Y, et al. (2001) Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol 133:746\u2013754","journal-title":"Br J Pharmacol"},{"key":"1289_CR200","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/00004872-200209000-00026","volume":"20","author":"J Tsukada","year":"2002","unstructured":"Tsukada J, Tahara A, Tomura Y, et al. (2002) Effects of YM471, an orally active non-peptide arginine vasopressin receptor antagonist of human vascular smooth muscle cells. J Hypertens 20:1807\u20131814","journal-title":"J Hypertens"},{"key":"1289_CR201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(02)01813-7","volume":"446","author":"J Tsukada","year":"2002","unstructured":"Tsukada J, Tahara A, Tomura Y, et al. (2002) Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist. Eur Pharmacol 446:129\u2013138","journal-title":"Eur Pharmacol"},{"key":"1289_CR202","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","volume":"104","author":"JE Udleson","year":"2001","unstructured":"Udleson JE, Smith WB, Hendrix GH, et al. (2001) Acute hemodynamic effects of conivaptan a dual VIA and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104:2417\u20132423","journal-title":"Circulation"},{"key":"1289_CR203","unstructured":"Uhlir O, et al. (1994) Clinical and hemodynamic effects of nebivolol in patients with mild to moderate congestive heart failure. JRF Clinical Research Report NEB = TCH-4"},{"key":"1289_CR204","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1067\/mcp.2000.110972","volume":"68","author":"H Ukkonen","year":"2000","unstructured":"Ukkonen H, Saraste M, Akkila J, et al. (2000) Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68:522\u2013531","journal-title":"Clin Pharmacol Ther"},{"issue":"3 pt 2","key":"1289_CR205","first-page":"H1454","volume":"272","author":"ME Ullian","year":"1997","unstructured":"Ullian ME, Islam MM, Robinson CJ, et al. (1997) Resistance to mineralcorticoids in Wistr\u2013Furth rats. Am J Physiol 272(3 pt 2): H1454\u20131461","journal-title":"Am J Physiol"},{"key":"1289_CR206","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2125.1998.00837.x","volume":"46","author":"NN Vachharajani","year":"1998","unstructured":"Vachharajani NN, Shyu WC, Smith RA, Greene DS (1998) The effects of age and gender n the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46:611\u2013613","journal-title":"Br J Clin Pharmacol"},{"key":"1289_CR207","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0928-0987(00)00120-2","volume":"11","author":"R Valjakka-Koskela","year":"2000","unstructured":"Valjakka-Koskela R, Hirvonen J, Monkkonen J, et al. (2000) Transdermal delivery of levosimendan. Eur J Pharm Sci 11:343\u2013350","journal-title":"Eur J Pharm Sci"},{"key":"1289_CR208","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.HYP.35.3.717","volume":"35","author":"PP Geel Van","year":"2000","unstructured":"Van Geel PP, Pinto YM, Voors AA, et al. (2000) Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 35:717\u2013721","journal-title":"Hypertension"},{"key":"1289_CR209","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(02)01972-6","volume":"449","author":"R Kerckhoven Van","year":"2002","unstructured":"Van Kerckhoven R, Lankhuizen I, van Veghel R, et al. (2002) Chronic vasopressin V(la) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats. Eur J Pharmical 449:135\u2013141","journal-title":"Eur J Pharmical"},{"key":"1289_CR210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/106002800303700217","volume":"37","author":"A Vichiendilokkul","year":"2003","unstructured":"Vichiendilokkul A, Tran A, Racine E (2003) Nesiritide: A novel approach for acute heart failure. Ann Pharmacother 37:247\u2013258","journal-title":"Ann Pharmacother"},{"key":"1289_CR211","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0306-3623(95)02060-8","volume":"27","author":"L Virag","year":"1996","unstructured":"Virag L, Hala O, Marion A, et al. (1996) Cardiac electrophysiologic effects levosimendan, a new calcium sensitizer. Gen Pharmacol 27:551\u2013556","journal-title":"Gen Pharmacol"},{"key":"1289_CR212","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(02)02101-5","volume":"450","author":"K Wada","year":"2002","unstructured":"Wada K, Tahara A, Arai Y, et al. (2002) Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. Eur J Pharmacol 450:169\u2013177","journal-title":"Eur J Pharmacol"},{"key":"1289_CR213","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1047951103000520","volume":"13","author":"H Wahlander","year":"2005","unstructured":"Wahlander H, Westerlind A, Lindstedt G, Lundberg PA, Holmgren D (2005) Increased levels of brain and atrial natriuretic peptides after the first palliative Operation, but not after a bidirectional Glenn anastomosis, in children with functionally univentricular hearts. Cardiol Young 13:268\u2013274","journal-title":"Cardiol Young"},{"key":"1289_CR214","doi-asserted-by":"crossref","first-page":"H2535","DOI":"10.1152\/ajpcell.1994.266.4.C1077","volume":"266","author":"P Wang","year":"1994","unstructured":"Wang P, Ba ZF, Chaudry IH (1994) Administration of tumor necrosis factor alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266:H2535\u2013H2541","journal-title":"Am J Physiol"},{"key":"1289_CR215","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/hc3001.091458","volume":"104","author":"MR Ward","year":"2001","unstructured":"Ward MR, Kanellakis P, Ramsey D, et al. (2001) Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467\u2013472","journal-title":"Circulation"},{"key":"1289_CR216","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/01.HYP.30.5.1121","volume":"30","author":"R Weber","year":"1997","unstructured":"Weber R, Pechere-Bertschi A, Hayoz D, et al. (1997) Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension 30:1121\u20131127","journal-title":"Hypertension"},{"key":"1289_CR217","doi-asserted-by":"crossref","first-page":"l794","DOI":"10.1016\/S0735-1097(99)00435-0","volume":"34","author":"AS Westheim","year":"1999","unstructured":"Westheim AS, Bostrom P, Christensen CC, et al. (1999) Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 34:l794\u20131801","journal-title":"Am Coll Cardiol"},{"key":"1289_CR218","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00467-003-1190-5","volume":"18","author":"CT White","year":"2003","unstructured":"White CT, Macpherson CF, Hurley RM, Matsell DG (2003) Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 18:1038\u20131043","journal-title":"Pediatr Nephrol"},{"key":"1289_CR219","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/euhj.1999.1547","volume":"20","author":"R Willienheimer","year":"1999","unstructured":"Willienheimer R, Dahlof B, Rydberg E, Erhardt L (1999) AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 20:997\u20131008","journal-title":"Eur Heart J"},{"key":"1289_CR220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/13543784.13.4.435","volume":"13","author":"BR Winkelmann","year":"2004","unstructured":"Winkelmann BR (2004) American Heart Association scientific sessions. Expert Opin Invest Drugs 13:435\u2013445","journal-title":"Expert Opin Invest Drugs"},{"key":"1289_CR221","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0002-8703(99)70226-7","volume":"137","author":"BR Winkelman","year":"1999","unstructured":"Winkelman BR, Russ AP, Nauck M, et al. (1999) Angiotensin M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 137:698\u2013705","journal-title":"Am Heart J"},{"key":"1289_CR222","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/0735-1097(93)90230-X","volume":"21","author":"T Wisenbaugh","year":"1993","unstructured":"Wisenbaugh T, Katz T, Davis J, et al. (1993) Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 21:1094\u20131110","journal-title":"J Am Coll Cardiol"},{"key":"1289_CR223","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00467-004-1483-3","volume":"19","author":"W Wong","year":"2004","unstructured":"Wong W, Mauger D (2004) Treatment of Wilms tumor-related hypertension with losartan and captopril. Pediatr Nephrol 19:805\u2013807","journal-title":"Pediatr Nephrol"},{"key":"1289_CR224","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(99)00379-9","volume":"327","author":"T Yatsu","year":"1999","unstructured":"Yatsu T, Tomura Y, Tahara A, et al. (1999) Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 327:239\u2013246","journal-title":"Eur J Pharmacol"},{"key":"1289_CR225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(96)00940-5","volume":"321","author":"T Yatsu","year":"1997","unstructured":"Yatsu T, Tomura Y, Tahara A, et al. (1997) Pharmacologic profile of YM087, a novel nonpeptide dual vasopressin V1 A and V2 receptor antagonist, in dogs. Eur J Pharmacol 321:225\u2013230","journal-title":"Eur J Pharmacol"},{"issue":"Suppl","key":"1289_CR226","first-page":"1l3P","volume":"114","author":"T Yatsu","year":"1999","unstructured":"Yatsu T, Tomura Y, Tahara A, et al. (1999) Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1 A\/V2 receptor antagonist. Nippon Yakurigaku Zasshi 114 (Suppl): 1l3P\u2013117P","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"1289_CR227","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1043661802002062","volume":"46","author":"T Yatsu","year":"2002","unstructured":"Yatsu T, Kusayama T, Tomura Y, et al. (2002) Effect of conivaptan a combined vasopressin V1A and V2 receptor antagonist, on vasopressin-induced cardiac and hemodynamic changes in anaesthetized dogs. Pharmacol Res 46:375\u2013381","journal-title":"Pharmacol Res"},{"key":"1289_CR228","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01108-4","volume":"333","author":"H Yokoshiki","year":"1997","unstructured":"Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 333:249\u2013259","journal-title":"Eur J Pharmacol"},{"key":"1289_CR229","first-page":"92","volume":"263","author":"TL Yue","year":"1992","unstructured":"Yue TL, Cheng HY, Lysko PG, et al. (1992) Carvedelol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J.Pharmacol Exp Ther 263:92\u201398","journal-title":"J.Pharmacol Exp Ther"},{"key":"1289_CR230","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, et al. (2003) Comittees CHARM investigators and Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme Inhibitors: the CHARM-Added trial. Lancet 362:767\u2013771","journal-title":"Lancet"},{"key":"1289_CR231","unstructured":"Zairis MN, Apostolatos C, Anatassiadis F, et al. (2004) Comparison of the effect of levosimendan or dobutamine or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) study. In: Program and abstracts of the European Society of Cardliology, Heart Failure Update 2004; June 12\u201315, Wroclaw Poland Abstract 273"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-006-1289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-006-1289-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-006-1289-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T10:12:04Z","timestamp":1558692724000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-006-1289-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,23]]},"references-count":231,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s00246-006-1289-0","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,23]]}}}